News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Invasive Breast Carcinoma → cancer profile · × Clear filters
Vepdegestrant, the first-in-class PROTAC degrader, approved for ESR1-mutated advanced breast cancer
On 1 May 2026 the FDA approved vepdegestrant (Veppanu), the first PROTAC protein degrader to reach clinical use, exclusively for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy. In the registrational VERITAC-2 trial (n=624, of whom 270 had ESR1-mutated tumours), median progression-free survival in the ES…
No Survival Benefit With Mastectomy in Younger, High-Risk Breast Cancer
A prospective study has found that mastectomy does not significantly improve survival outcomes compared with less aggressive surgery in younger women with high-risk locoregionally advanced breast cancer. Despite mastectomy being the predominant surgical approach in this age group, the data suggest the more radical procedure offers no meaningful survival advantage. The findings challenge current cl…
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
A study published in the Journal of Clinical Oncology presents findings from the PREDICT trial, which evaluated ultrasensitive circulating tumor DNA (ctDNA) as a tool for detecting minimal residual disease (MRD) in breast cancer patients. The research demonstrates the potential of liquid biopsy-based ctDNA assays to identify residual cancer cells that remain after treatment, which could help clini…
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
A phase II trial (ABC study) published in the Journal of Clinical Oncology evaluated the combination of adebrelimab (anti-PD-L1) and bevacizumab with platinum-based chemotherapy (cisplatin or carboplatin) in patients with triple-negative breast cancer (TNBC) and brain metastases — an aggressive subtype with very limited treatment options for CNS disease. The study addresses a critical unmet need, …
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
A landmark patient-level meta-analysis published in The Lancet, encompassing 15,000 premenopausal women across 23 randomised trials, has demonstrated that ovarian function suppression (OFS) significantly reduces the 15-year risk of breast cancer recurrence and death in ER-positive early breast cancer. The benefit persisted even in women already receiving chemotherapy or tamoxifen, strengthening th…
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials
A pooled analysis of five randomised trials, published in The Lancet Oncology, evaluated whether performing sentinel lymph node biopsy (SLNB) or complete axillary lymph node dissection (cALND) solely to determine eligibility for CDK4/6 inhibitor therapy is justified in early breast cancer. The researchers found that the number needed to diagnose and treat was very high, the procedures added substa…
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
A large reconstructed individual patient data meta-analysis of phase 3 randomized trials published in The Lancet Oncology confirms that adding CDK4/6 inhibitors to endocrine therapy significantly improves both progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Crucially, the analysis reveals clinically meaningful differe…
European Breast Cancer Conference 2026
Preliminary results from the pilot phase of the ADARNAT trial, a phase 3 multicentre randomised study across 23 Spanish hospitals, suggest that axillary radiotherapy may safely replace axillary lymph node dissection in breast cancer patients with limited nodal disease after neoadjuvant therapy. The study enrolled 272 patients with breast cancer (cT1–T4b, cN0–cN1) who had 1–2 positive sentinel lymp…
Nature: blood biomarker proposed to predict immunotherapy response in breast cancer
Nature describes work identifying a blood-measured biomarker intended to predict which patients with certain breast cancer types will respond to immunotherapy. The question matters clinically because checkpoint inhibitors benefit only a subset of patients and there is currently no reliable way to identify them in advance. The available note gives neither the name of the biomarker, nor the number o…
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
A phase III randomized noninferiority trial (neoCARHP), published in the Journal of Clinical Oncology, investigated whether carboplatin can be safely omitted from the neoadjuvant regimen of taxane plus trastuzumab and pertuzumab in patients with HER2-positive breast cancer. The trial addresses a critical clinical question about treatment de-escalation, aiming to reduce the well-known toxicity burd…